Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Jun 2011

Masago Katsuhiro, Miura Masako, Toyama Yoshiro, Togashi Yosuke, Mishima Michiaki

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Papillary
Share to Antineoplastic Agents
Share to Carcinoma, Signet Ring Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epidermal Growth Factor

Share to Erlotinib Hydrochloride

Share to Immunohistochemistry

Share to Quinazolines

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 21422425
DOI: 10.1200/JCO.2010.34.0216

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21.PMID 21422425Read ↗

First case of A859T epidermal growth factor receptor mutation responding to erlotinib.Semantic proximity Read ↗

Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.Semantic proximity Read ↗

Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.Semantic proximity Read ↗

Successful Salvage Therapy With a High Dose of Furmonertinib in a Case of Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion.Semantic proximity Read ↗

Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.Semantic proximity Read ↗

Case report: Long-term survival with anlotinib in a metastatic parathyroid carcinoma patient harboring EGFR-sensitizing mutationSemantic proximity Read ↗

Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.Semantic proximity Read ↗

Two rare exon 21 EGFR mutations in patients treated with gefitinib.Semantic proximity Read ↗

Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis.Semantic proximity Read ↗

Response and acquired resistance to everolimus in anaplastic thyroid cancer.Semantic proximity Read ↗

Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience.Semantic proximity Read ↗

Response to Erlotinib in a Patient with Compound EGFR L747S and Exon 19 Deletion.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.